|[January 14, 2014]
Humanetics Corporation Granted Approval by the National Cancer Institute to Proceed With Cancer Treatment Study
MINNEAPOLIS --(Business Wire)--
Following successful completion of Phase I of a Fast Track Contract,
Minneapolis-based Humanetics Corporation (Humanetics), together with its
research collaborators at Henry Ford Hospital in Detroit, has been
granted approval from the National Cancer Institute (NCI) to move to
Phase II of the contract. This phase will include an exploratory
clinical trial to evaluate the ability of Humanetics' proprietary
compound, BIO 300, to lessen the normal tissue side effects from
chemotherapy and radiation associated with lung cancer treatment.
The trial will be led by Dr. Benjamin Movsas, Chairman of the Department
of Radiation Oncology at Henry Ford Hospital. Dr. Movsas and his team
are particularly interested in preserving the quality of life among
non-small cell lung cancer patients undergoing chemotherapy and
radiation treatment. A secondary endpoint for the clinical trial will
evaluate local control of tumor response.
"This is an important clinical trial to explore a novel strategy to
protect normal lung tissue and thereby enhance the quality of life for
lung cancer patients receiving chemoradiation therapy," says Dr. Movsas.
Dr. John Popovich J., President and CEO of Henry Ford Hospital adds:
"We are very excited to be able to soon offer this very timely trial at
Henry Ford Hospital."
Humanetics will file an Investigational New Drug Application prior to
starting the trial. There are currently no approved drugs to protect
normal lung tissue from the damage caused by radiation and chemotherapy
Lung cancer is the most common cause of cancer-related deaths in the
United States. This year, an estimated 228,000 new cases of lung cancer
will be diagnosed, and lung cancer will be responsible for approximately
159,000 deaths. Non-small cell lung cancer is the most common type of
lung cancer, comprising approximately 85% of all cases. In spite of
ever-increasing attention, survival rates for lung cancer have not
significantly improved over the past 40 years.
"We're looking forward to taking this significant next step toward
improving outcomes for this devastating disease," said Ronald J. Zenk,
CEO of Humanetics Corporation.
The clinical trial is expected to begin in mid-2014.
About Humanetics Corporation
Humanetics Corporation is a clinical-stage specialty pharmaceutical
company engaged in the discovery, development and commercialization of
proprietary drugs, medical foods and consumer products in markets with
urgent and unmet needs. For more information, visit www.humaneticscorp.com.
About Henry Ford Hospital
Henry Ford Hospital, the flagship facility for Henry Ford Health System,
is an 802-bed tertiary care hospital, education and research complex.
The hospital is staffed by the Henry Ford Medical Group, one of the
nation's largest and oldest group practices with 1,200 physicians in
more than 40 specialties. In 2011, the hospital opened the Innovation
Institute, a project aimed at shaping the future of medicine. The
hospital and campus is led by President and CEO John Popovich Jr., M.D.
To learn more, visit HenryFord.com.
[ Back To TMCnet.com's Homepage ]